Company Overview and News

0
Melbourne Express: Thursday, July 19, 2018

8h smh.com.au
As soon as you step outside you'll notice it's very windy and there has actually been a severe weather warning issued for a lot of Victoria.
SESG

0
Wild winds of more than 100km/h as storm hits Melbourne

2018-07-17 smh.com.au
A thunderstorm front with the potential to produce winds of more than 100km/h has hit Melbourne this afternoon, damaging trees and properties and causing power outages and train delays.
SESG

0
Melbourne weather: Thick fog blankets the city, delays flights

2018-06-27 smh.com.au
A thick, low-lying fog is lingering over Melbourne with flights delayed and drivers urged to take extra care on the roads.
SESG

344
Intelsat S.A. And SES S.A.: To The Moon

2018-06-27 seekingalpha
Intelsat and SES stand to benefit massively if the FCC permits them to sell access to their spectrum in order to accelerate the deployment of 5G.
SESG FOX VOD TMUS CMCSA I CHTR S T AAPL VZ QCOM INTC SBAC DIS

2
Eutelsat Won't Bid for Inmarsat, Clearing Way for EchoStar - Bloomberg

2018-06-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SATS SESG VSAT EUTLF ETCMY ISAT

0
SpaceX Launches Satellite for SES in Its 11th Mission This Year - Bloomberg

2018-06-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SESG

0
SES shares surge 12% after first-quarter earnings report

2018-04-27 marketwatch
SES SA engages in the provision of satellite and ground communications solutions. It focuses on value-added, end-to-end solutions in SES video and SES networks. The company was founded on March 1, 1985 and is headquartered in Betzdorf, Luxembourg. (See Full Profile)
SESG

0
Flooding from ex-cyclone Nora in Queensland

2018-03-25 smh.com.au
Cairns and Port Douglas are mopping up after torrential rain from ex-cyclone Nora caused flash flooding in Queensland's far north.
SESG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...